National Immunisation Programme Redirecting...

Image is of a real patient

This website is organised and funded by GSK. Adverse event reporting and prescribing information can be found below the registration form.

Maximise the summer period to help protect your eligible patients against shingles

Vaccine uptake data for the Shingles National Immunisation Programme in England^1,2

Immunocompetent
65-year-olds

32.6%

Of the estimated 158,166 adults who turned 65 between 1st Sept 2023 and 30th Nov 2023 had received their first dose by 23rd July 2024

Immunocompetent
70-year-olds

43.0%

Of the estimated 128,220 adults who turned 70 between 1st Sept 2023 and 30th Nov 2023 had received their first dose by 23rd July 2024

UK Health Security Agency. Shingrix vaccine uptake report (adults eligible from September 2023 to May 2024 and vaccinated to the end of July 2024): England. Updated April 2025. Available at: https://www.gov.uk/government/publications/shingles-immunisation-programme-shingrix-evaluation-reports/596b592d-b05d-4558-b5f4-7e2c2cb51e3c (Last Accessed: June 2025)
UK Health Security Agency. Shingles Immunisation Programme [SHINGRIX]: Evaluation Reports. Shingrix vaccine coverage by ICB and LA (England), September 2023 to February 2024 (vaccinated to end-April 2024). Updated April. 2025 Available at: https://www.gov.uk/government/publications/shingles-immunisation-programme-shingrix-evaluation-reports (Last Accessed: June 2025)

Organised and funded by GSK. For UK healthcare professionals. This site contains promotional material.

Register to stay updated with the latest peer-led, practical resources designed to support programme implementation!

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search for MHRA Yellowcard in the Google Play or Apple App store. Adverse events should also be reported to GlaxoSmithKline on 0800 221 441 or UKSafety@gsk.com.

For the SHINGRIX® (herpes zoster vaccine, recombinant, adjuvanted) prescribing information, click here.